Horizon Pharma (HZNP) PT Lowered to $24 at BMO Capital on FA Miss; Maintains 'Outperform'
Tweet Send to a Friend
BMO Capital analyst Gary Nachman lowered his price target on Horizon Pharma (NASDAQ: HZNP) to $24.00 (from $29.00) but maintained ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE